NeurogesX

company

About

NeurogesX develops and commercializes therapies for chronic peripheral neuropathic pain.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$8.40M
Industries
Biotechnology,Medical,Medical Device,Neuroscience
Founded date
Jan 1, 1998
Number Of Employee
51 - 100
Operating Status
Active

NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$86.26M
NeurogesX has raised a total of $86.26M in funding over 2 rounds. Their latest funding was raised on Dec 1, 2005 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 1, 2005 Series D $20M 1 Detail
Feb 24, 2004 Series C $35M 2 Detail
Jan 23, 2002 Series B $22.86M 1 Detail
Jun 1, 2000 Series A $8.40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
NeurogesX is funded by 2 investors. ARCH Venture Partners and Diamond Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series D
Diamond Capital Management Series C